Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Eribulin for Locally Advanced Refractory or Metastatic Salivary Gland Cancers

NCT01613768 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT01613768
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01613768 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Eribulin for Locally Advanced Refractory or Metastatic Salivary Gland Cancers
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Completed
Start date
May 8, 2012
Completion date
August 23, 2017
Enrollment
29 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent salivary gland cancer, stage iva salivary gland cancer, stage ivb salivary gland cancer, stage ivc salivary gland cancer